• Mink Therapeutics posted a first-quarter net loss of USD 2.74 million, narrowing from USD 2.77 million a year earlier, while loss per share improved to USD 0.57 from USD 0.70.
• Cash and cash equivalents fell to USD 9.53 million at March 31, 2026 from USD 13.36 million at end-2025, while cash used in operations rose to USD 1.73 million from USD 1.34 million a year earlier.
• During the quarter, it repaid about USD 5.2 million tied to the Agenus convertible note and raised about USD 3 million via its at-the-market sales agreement.
• MiNK initiated a randomized Phase 2 trial of agenT-797 in severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026.
• CEO Jennifer Buell said the off-the-shelf iNKT therapy is designed for use without lymphodepletion or HLA matching in settings where speed and tolerability matter, including severe acute lung injury and critical illness.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150730PRIMZONEFULLFEED9720943) on May 15, 2026, and is solely responsible for the information contained therein.